Project Grant R21CA293274
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $202K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), provides $627,148.00 to the University of Maryland, College Park to develop an injectable, low-cost ablative therapy based on ethyl cellulose-ethanol gel for treating cervical dysplasia. The goal is to create an alternative to current costly and technically complex cervical cancer prevention solutions that are not practical for use in medically underserved regions. The project...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $442,750.00 to New York University (NYU) to conduct a study on implementation strategies for cervical cancer control policies in Africa. The project aims to: (A) Engage a network of experts from African low- and middle-income countries (LMICs) and global agencies through a Delphi process to identify determinants of policy implementation success, using the Consolidated...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $371,161 to develop advanced AI-based risk models for cervical cancer screening in low-resource settings. The project aims to leverage time-series imaging data and self-supervised learning to enhance the diagnostic accuracy of automated visual evaluation (AVE) models. The goal is to create a comprehensive risk stratification system that combines imaging data, HPV...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...
- This federal Project Grant award of $317,420 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop and validate a patient-ready callascope device for cervical imaging and cancer prevention in low- and middle-income countries (LMICs). The primary focus is on creating point-of-care solutions for screening, diagnosis, and treatment that can be delivered by community health workers and midwives, thereby increasing access to care. Key...
- The University of North Carolina at Chapel Hill (UNC-CH) was awarded a $688,458 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a pilot Phase IIA randomized placebo-controlled trial evaluating the safety, adherence, and preliminary efficacy of using 5-fluorouracil (5FU) as an adjuvant intravaginal therapy following thermal ablation to improve human papillomavirus (HPV) treatment outcomes in women living with...
- The University of Alabama at Birmingham (UAB) received a $192,780 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to implement and optimize a bundled screening program for breast and cervical cancer in a resource-limited setting in sub-Saharan Africa. The project aims to 1) establish the reach and effectiveness of the bundled screening program across stationary and mobile clinics, and 2) identify the implementation outcomes of...
- The National Institutes of Health National Cancer Institute awarded a $246,493 project grant to Centro De Estudios De Estado Y Sociedad Cedes, an Argentine non-profit organization, under the federal Cancer Cause and Prevention Research program (CFDA 93.393). The grant funds the development and evaluation of a mobile application intervention to support women who have undergone HPV testing and increase their retention for follow-up cervical cancer care in Argentina. The key goals are to provide...
- This federal Project Grant award of $564,414.00 was provided by the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), to assess the feasibility of gastric cancer screening in the United States. The award was granted to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research aimed at developing risk models and identifying high-risk individuals for potential gastric cancer screening. The research...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is supporting research to develop a promising low-toxicity therapeutic strategy for cervical cancer. The $376,490 award to the University of Oklahoma Health Sciences Center will investigate combining a C-MYC inhibitor (MYCI975) with the novel investigational agent SHETA2 to target metabolic reprogramming in cervical cancer. Preliminary studies indicate SHETA2 disrupts mitochondrial function and...